Pasireotide LA is under clinical development by Recordati and currently in Phase II for Hyperprolactinaemia. According to GlobalData, Phase II drugs for Hyperprolactinaemia does not have sufficient historical data to build an indication benchmark PTSR for Phase II. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the Pasireotide LA LoA Report. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Pasireotide LA overview
Pasireotide (Signifor LAR/ Signifor LP) is a synthetic long-acting cyclic hexapeptide somatostatin analogue. It is formulated extended release powder for suspension for intramuscular route of administration for long acting release. It is indicated to treat adult patients with acromegaly for whom surgery is not an option or has not been curative and who are inadequately controlled on treatment with a first-generation somatostatin analogue (SSA) and for the treatment of patients with Cushing’s disease for whom pituitary surgery is not an option
or has not been curative.
Pasireotide LAR was under development for the treatment of neuroendocrine carcinoma of the lung and thymus.
It is also under development for the treatment of prolactinoma. It was also under development of hormone refractory (castration resistant, androgen-independent) prostate cancer as first line and second line therapy, neuroendocrine gastro-entero-pancreatic tumors, Nelson syndrome, relapsed/refractory multiple myeloma, carcinoid tumor, relapsed or refractory small cell lung cancer, pancreatic cancer, Merkel cell carcinoma, metastatic melanoma, gastrointestinal malignancies including colon cancer, gastric cancer, esophageal cancer, graves’ ophthalmopathy, pituitary tumor, uveal melanoma and meningiomas.
Recordati overview
Recordati, a subsidiary of Fimei SpA, is a pharmaceutical company that researches, develops, manufactures and markets pharmaceuticals. The company offers pharmaceuticals for cardiovascular diseases, central nervous system disorders, dermatology, musculoskeletal disorders and analgesia, and urology diseases. It also offers cosmetics, dietary supplements, pregnancy test products, over-the-counter (OTC) and non-prescription pharmaceuticals, anti-infectives, and others. It manufactures pharmaceutical chemicals such as active pharmaceutical ingredients (APIs) and intermediates. The company sells its pharmaceuticals directly in the countries of its operations and through licensees in other places. Recordati is headquartered in Milan, Italy.
For a complete picture of Pasireotide LA’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
